ReviewFrontiers in physiology2022
Advances in Our Clinical Understanding of Autonomic Regulation Therapy Using Vagal Nerve Stimulation in Patients Living With Heart Failure.
Review in Frontiers in physiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- The efficacy of transcutaneous vagus nerve stimulation in heart failure management - a systematic review and meta-analysis.BMC cardiovascular disorders · 2025Pooled it
- The Optimal Dosage and Duration of ω-3 PUFA Supplementation in Heart Failure Management: Evidence from a Network Meta-Analysis.Advances in nutrition (Bethesda, Md.) · 2025Pooled it
- Hypertension: a missing piece in HFpEF?Hypertension research : official journal of the Japanese Society of Hypertension · 2026Review
- A Holistic and Dynamic Network-Level View of the Autonomic Nervous System.Annual review of biomedical engineering · 2026Review
- A fully degradable triboelectric vagus nerve stimulator for attenuating cardiac remodeling and heart failure at different stages.Nature communications · 2026Article
- Comparative clinical outcomes and safety of finerenone, SGLT2 inhibitors, RAS inhibitors and ARNI in heart failure with preserved or mildly reduced ejection fraction: a systematic review and network meta-analysis.Frontiers in pharmacology · 2026Review
- Sympathetic Nervous System in Heart Failure: Targets for Treatments.Current hypertension reports · 2025Review
- Autonomic neuromodulation for cardiomyopathy associated with metabolic syndrome - Prevention of precursors for heart failure with preserved ejection fraction.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Review
- Transcriptional response of the heart to vagus nerve stimulation.Physiological genomics · 2024Article
- Transcriptional response of the heart to vagus nerve stimulation.Physiological genomics · 2024Article
- The Fifth Bioelectronic Medicine Summit: today's tools, tomorrow's therapies.Bioelectronic medicine · 2023Article
- A Comparative Review of Vagal Nerve Stimulation Versus Baroreceptor Activation Therapy in Cardiac Diseases.Cureus · 2023Review
- Vagus Nerve Stimulation and Its Cardioprotective Abilities: A Systematic Review.Journal of clinical medicine · 2023Review
- Chronic vagus nerve stimulation in patients with heart failure: challenge or failed translation?Frontiers in cardiovascular medicine · 2023Review
- Sympathetic components in left and right human cervical vagus nerve: implications for vagus nerve stimulation.Frontiers in neuroanatomy · 2023Article
- Neuroimmunomodulation of vagus nerve stimulation and the therapeutic implications.Frontiers in aging neuroscience · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 12 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ANTHEM-HF, INOVATE-HF, and NECTAR-HF clinical studies of autonomic regulation therapy (ART) using vagus nerve stimulation (VNS) systems have collectively provided dose-ranging information enabling the development of several working hypotheses on how stimulation frequency can be utilized during VNS for tolerability and improving cardiovascular outcomes in patients living with heart failure (HF) and reduced ejection fraction (HFrEF). Changes in heart rate dynamics, comprising reduced heart rate (HR) and increased HR variability, are a biomarker of autonomic nerve system engagement and cardiac control, and appear to be sensitive to VNS that is delivered using a stimulation frequency that is similar to the natural operating frequency of the vagus nerve. Among prior studies, the ANTHEM-HF Pilot Study has provided the clearest evidence of autonomic engagement with VNS that was delivered using a stimulation frequency that was within the operating range of the vagus nerve. Achieving autonomic engagement was accompanied by improvement from baseline in six-minute walk duration (6MWD), health-related quality of life, and left ventricular EF (LVEF), over and above those achieved by concomitant guideline-directed medical therapy (GDMT) administered to counteract harmful neurohormonal activation, with relative freedom from deleterious effects. Autonomic engagement and positive directional changes have persisted over time, and an exploratory analysis suggests that improvement in autonomic tone, symptoms, and physical capacity may be independent of baseline NT-proBNP values. Based upon these encouraging observations, prospective, randomized controlled trials examining the effects on symptoms and cardiac function as well as natural history have been warranted. A multi-national, large-scale, randomized, controlled trial is well underway to determine the outcomes associated with ART using autonomic nervous system engagement as a guide for VNS delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.